Recent Advances and Research Progress Regarding Monoclonal Antibodies for Chronic Graft-versus-host Disease

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Oct 15

PMID 39403509

Authors

Shiqin Huang

Xianjing Cheng

Guancui Yang

Ruihao Huang

Yimei Feng

Lingyu Zeng

Tao Wu

Qingxiao Song

Xiaoqi Wang

Xi Zhang

Affiliations

Soon will be listed here.

Abstract

Chronic graft-versus-host disease (cGVHD) is one of the leading causes of mortality following allogeneic hematopoietic stem cell transplantation (HSCT), with only 50 % of patients responding to conventional corticosteroids with or without calcineurin inhibitors. Monoclonal antibodies (mAbs), such as CD20 mAbs, are the first drugs to demonstrate greater efficacy than corticosteroids in first-line treatment of cGVHD. This review provides a comprehensive overview of recent developments in the clinical utilization of mAbs to prevent and treat cGVHD. We also describe the application of drugs with target sites that are identical to or linked to those of cGVHD in autoimmune diseases as potential future treatments for cGVHD. In summary, we collected known evidence concerning the clinical research progress on the use of mAbs in the prevention and treatment of cGVHD and identified drugs with the same target sites in autoimmune diseases for potential future applications in cGVHD, with the goal of providing suggestions and inspiration for optimizing cGVHD treatment strategies and research directions.

References

Zhang X, Chen J, Han M, Huang H, Jiang E, Jiang M . The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021; 14(1):145. PMC: 8441240. DOI: 10.1186/s13045-021-01159-2. View

Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D . Mitigation of gastrointestinal graft--host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. Haematologica. 2022; 108(1):250-256. PMC: 9827178. DOI: 10.3324/haematol.2022.281309. View

Coghill J, Sarantopoulos S, Moran T, Murphy W, Blazar B, Serody J . Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood. 2011; 117(12):3268-76. PMC: 3069668. DOI: 10.1182/blood-2010-12-290403. View

Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S . Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplant. 2022; 57(3):499-501. DOI: 10.1038/s41409-021-01560-y. View

Berry S, Dossou C, Kashif A, Sharifinejad N, Azizi G, Hamedifar H . The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases. Int Immunopharmacol. 2021; 102:108402. DOI: 10.1016/j.intimp.2021.108402. View

Golden-Mason L, Curry M, Nolan N, Traynor O, McEntee G, Kelly J . Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver. Hepatology. 2000; 31(6):1251-6. DOI: 10.1053/jhep.2000.7713. View

Pierini A, Strober W, Moffett C, Baker J, Nishikii H, Alvarez M . TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood. 2016; 128(6):866-71. PMC: 4982455. DOI: 10.1182/blood-2016-04-711275. View

Tierney E, Evans P, Broderick V, Wynn R, Irvine A . Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease. Br J Dermatol. 2023; 190(4):581-583. DOI: 10.1093/bjd/ljad526. View

Landells I, Marano C, Hsu M, Li S, Zhu Y, Eichenfield L . Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015; 73(4):594-603. DOI: 10.1016/j.jaad.2015.07.002. View

10.

Pidala J, Kurland B, Chai X, Majhail N, Weisdorf D, Pavletic S . Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011; 117(17):4651-7. PMC: 3099579. DOI: 10.1182/blood-2010-11-319509. View

11.

Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P . Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood. 2010; 116(16):3080-8. DOI: 10.1182/blood-2010-05-286856. View

12.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

13.

Pidala J, Kim J, Betts B, Alsina M, Ayala E, Fernandez H . Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biol Blood Marrow Transplant. 2015; 21(6):1074-82. PMC: 5757506. DOI: 10.1016/j.bbmt.2015.03.014. View

14.

Cutler C, Kim H, Bindra B, Sarantopoulos S, Ho V, Chen Y . Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013; 122(8):1510-7. PMC: 3750344. DOI: 10.1182/blood-2013-04-495895. View

15.

. Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Study. Gastroenterol Hepatol (N Y). 2024; 19(12 Suppl 9):2-3. PMC: 10910377. View

16.

Wingard J, Majhail N, Brazauskas R, Wang Z, Sobocinski K, Jacobsohn D . Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230-9. PMC: 3107742. DOI: 10.1200/JCO.2010.33.7212. View

17.

Bernard F, Uppungunduri C, Meyer S, Cummins M, Patrick K, James B . Excellent overall and chronic graft-versus-host-disease-free event-free survival in Fanconi anaemia patients undergoing matched related- and unrelated-donor bone marrow transplantation using alemtuzumab-Flu-Cy: the UK experience. Br J Haematol. 2021; 193(4):804-813. DOI: 10.1111/bjh.17418. View

18.

Klobuch S, Weber D, Holler B, Edinger M, Herr W, Holler E . Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease-single center experience. Ann Hematol. 2019; 98(10):2399-2405. DOI: 10.1007/s00277-019-03768-x. View

19.

Kitko C, Arora M, DeFilipp Z, Zaid M, Di Stasi A, Radojcic V . Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study. J Clin Oncol. 2022; 41(10):1864-1875. PMC: 10082302. DOI: 10.1200/JCO.22.00958. View

20.

Adams R, Carter-Cusack D, Llanes G, Hunter C, Vinnakota J, Ruitenberg M . CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice. Blood. 2023; 143(10):912-929. DOI: 10.1182/blood.2023022040. View